GlaxoSmithKline (GLAXO) | Stock Overview & Key Data
GlaxoSmithKline Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹3,872.00 on March 28, 2016
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
GlaxoSmithKline
GLAXO
|
422.67B Large-cap | -3.19% | -13.28% | -11.99% | -17.96% | -13.88% | -35.63% | 50.14% | 45.44% | -39.87% | -9.78% | 324.98% |
|
Pfizer
PFIZER
|
218.82B Large-cap | -0.22% | -8.81% | -4.87% | -9.94% | -8.09% | -23.35% | 16.94% | -16.55% | 139.64% | 232.33% | 479.18% |
|
Sanofi Consumer
SANOFICONR
|
105.86B Mid-cap | 0.01% | -3.05% | 10.56% | 2.80% | 3.48% | -8.68% | -5.84% | -5.84% | -5.84% | -5.84% | -5.84% |
|
Marksans Pharma
MARKSANS
|
86.20B Mid-cap | 5.80% | 20.40% | 51.59% | 31.03% | 38.86% | -2.65% | 181.04% | 197.61% | 488.28% | 10,872.61% | 2,742.00% |
|
Sanofi India Limited
SANOFI
|
79.35B Mid-cap | 2.46% | 0.71% | -5.74% | -22.80% | -20.92% | -49.23% | -54.97% | -58.99% | -25.65% | 55.45% | 103.00% |
|
Senores
SENORES
|
41.04B Small-cap | 27.43% | 22.17% | 72.40% | 57.40% | 55.27% | 131.62% | 125.07% | 125.07% | 125.07% | 125.07% | 125.07% |
Ownership & Short Interest
Calculate Your GlaxoSmithKline Investment Returns
Long-Term Investment Performance Analysis
GlaxoSmithKline stock price in Jul 2016 was ₹3,399.10, A ₹1,000.00 lump sum investment in GlaxoSmithKline made 9 years ago would be worth approximately ₹622.22 today, representing a negative return of -37.78%. This translates to an annualized return (CAGR) of -4.68%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is GLAXO's 52-week high and low?
- In the last 52 weeks, GlaxoSmithKline reached a high of ₹3,500.00 (on June 27, 2025) and a low of ₹2,088.10 (on N/A).
- What is the market cap and P/E ratio for GLAXO?
- Curious about GlaxoSmithKline's size and valuation? Its market capitalization stands at 422.67B. When it comes to valuation, the P/E ratio (trailing twelve months) is 41.55, and the forward P/E (looking ahead) is 36.46.
- Does GLAXO pay dividends? If so, what's the yield?
- Yes, GlaxoSmithKline is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.65%, and the company has paid an average of ₹59.33 per share annually over the past 3 years.
- Who are GlaxoSmithKline's main competitors or similar companies to consider before investing?
When looking at GlaxoSmithKline, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Pfizer
PFIZER218.82B Healthcare Drug Manufacturers - General -23.35% 16.94% Sanofi Consumer
SANOFICONR105.86B Healthcare Drug Manufacturers - General -8.68% -5.84% Marksans Pharma
MARKSANS86.20B Healthcare Drug Manufacturers - General -2.65% 181.04% Sanofi India Limited
SANOFI79.35B Healthcare Drug Manufacturers - General -49.23% -54.97% Senores
SENORES41.04B Healthcare Drug Manufacturers - General 131.62% 125.07% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for GlaxoSmithKline Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of GlaxoSmithKline's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 47.54%, the Debt to Equity ratio from the most recent quarter is 2.09, and its Gross Profit Margin stands at 65.06%.
- What is the recent revenue and earnings growth for GLAXO?
- Looking at GlaxoSmithKline's growth, its revenue over the trailing twelve months (TTM) was INR38B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.70%, and quarterly earnings saw a YoY growth of 28.60%.
- How much of GLAXO stock is held by insiders and institutions?
- Wondering who owns GlaxoSmithKline stock? Company insiders (like executives and directors) hold about 75.65% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 7.47%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.